Breadcrumb

[A19-85] Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-10-02 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 108 kB] (German version) Further documents
Note:

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-15.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A16-77] Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54
Status: Commission completed

[A16-54] Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-04-02 Extract of dossier assessment (German version) 108 kBPDFdownload file
2020-04-02 Dossier assessment (German version) 892 kBPDFdownload file

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-15.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close